NCT00087477终止1 期
A Pilot Study of Pivanex, a Histone Deacetylase Inhibitor, in Patients With Malignant Melanoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 14
- 试验地点
- 2
研究概览
简要总结
This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
详细描述
Rationale: Pivanex is a histone deacetylase inhibitor that induces tumor differentiation, inhibits proliferation, and induces apoptosis. Pivanex has been generally well tolerated in clinical trials and has shown preliminary evidence of efficacy in patients with non-small cell lung cancer. Pivanex has shown in-vitro and in-vivo evidence of anti-tumor activity against melanoma and, therefore, represents a promising therapeutic approach to patients with malignant melanoma.
Purpose: This open-label trial will determine the response rate of Pivanex in patients with malignant melanoma.
Objectives:
- Determine time to disease progression
- Determine overall survival
- Determine the safety profile of Pivanex in malignant melanoma
Outline: This is an open-label, single center study in patients with malignant melanoma whose disease has progressed or failed to respond to chemotherapy or Interleukin-2 (IL-2). Patients will be treated with 2.5 g/m2 of Pivanex administered intravenously over 6 hours daily on Days 1 - 3.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed melanoma, previously treated with chemotherapy or IL-2
- •Recurrent or progressive disease after treatment.
- •Measurable disease.
- •Males and females, age ≥ 18 years.
- •Adequate renal function with creatinine ≥ 1.5 mg/dl.
- •Adequate liver function with alkaline phosphatase <= 2.5 X upper limit of normal, SGOT and SGPT <= 1.5 X upper limit of normal and total bilirubin <= 1.5 X upper limit of normal.
- •Adequate bone marrow function: platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, and absolute neutrophil count (ANC)≥ 1,500 cells/mm
- •Able to give informed consent.
- •Must have discontinued previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity. Localized palliative radiation therapy to non-target lesions is permitted within the four weeks prior to randomization.
- •A predicted life expectancy of at least 6 months.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
排除标准
- •Receipt of more than three (3) systemic treatment regimens for malignant melanoma (including IL-2).
- •A second malignancy within the last 5 years other than curatively treated carcinoma-in-situ or non-melanoma skin cancer.
- •Pregnant or lactating females. Females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control.
- •Known HIV-positive patients.
- •Acute medical problems, such as ischemic heart or lung disease or uncontrolled systemic infection.
- •Patients with any underlying medical conditions or circumstance, which would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints.
- •Patients receiving investigational agents within 4 weeks of randomization.
- •Known allergy to reagents in the study.
- •Symptomatic or untreated brain metastases - Patients with brain metastases are eligible if they are clinically and neurologically stable for ≥ 4 weeks since therapy (radiation therapy, radiosurgery/gamma knife, surgical resection) as determined by the investigator and either off corticosteroids or on a stable dose of corticosteroids.
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic LeukemiaLeukemia, Lymphocytic, ChronicLymphoma, Small LymphocyticNCT00083473Titan Pharmaceuticals28
已完成
1 期
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaB-cell Adult Acute Lymphoblastic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueAnaplastic Large Cell LymphomaHepatosplenic T-cell LymphomaNodal Marginal Zone B-cell LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Multiple MyelomaSplenic Marginal Zone LymphomaT-cell Adult Acute Lymphoblastic LeukemiaWaldenström MacroglobulinemiaPost-transplant Lymphoproliferative DisorderNCT00918333Mayo Clinic124
已完成
2 期
Belinostat in Treating Patients With Myelodysplastic Syndromesde Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesSecondary Myelodysplastic SyndromesNCT00357162National Cancer Institute (NCI)21
已完成
1 期
Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) PatientsColon CancerNCT02891538The University of Texas Health Science Center at San Antonio51
Unknown
1 期
Tinostamustine and Nivolumab in Advanced MelanomaMalignant MelanomaNCT03903458Markus Joerger21